Immunogenetic effects of low dose (CEM43 30) magnetic nanoparticle hyperthermia and radiation in melanoma cells

Kayla E. A. Duval, Nicholas A. Vernice, Robert J. Wagner, Steven N. Fiering, James D. Petryk, Gabriela J. Lowry, Steven S. Tau, John Yin, Georgia R. Houde, Aneeq S. Chaudhry and P. Jack Hoopes

Department of Engineering, Dartmouth College, Hanover, NH, USA
Geisel School of Medicine, Dartmouth College, Hanover, NH, USA

ABSTRACT

Objective: In this in vitro study we have used an RNA quantification technique, nanoString, and a conventional protein analysis technique (Western Blot) to assess the genetic and protein expression of B16 murine melanoma cells following a modest magnetic nanoparticle hyperthermia (mNPH) dose equivalent to 30 minutes @ 43°C (CEM43 30) and/or a clinically relevant 8 Gy radiation dose.

Methods: Melanoma cells with mNPs(2.5 μg Fe/106 cells) were pelleted and exposed to an alternating magnetic field (AMF) to generate the targeted thermal dose. Thermal dose was accurately monitored by a fiber optic probe and automatically maintained at CEM43 30. All cells were harvested 24 hours after treatment.

Results: The mNPH dose demonstrated notable elevations in the thermotolerance/immunogenic HSP70 gene and a number of chemotactant and toll-like receptor gene pathways. The 8 Gy dose also upregulated a number of important immune and cytotoxic genetic and protein pathways. However, the mNPH/radiation combination was the most effective stimulator of a wide variety of immune and cytotoxic genes including HSP70, cancer regulating chemokines CXCL10, CXCL11, the T-cell trafficking chemokine CXCR3, innate immune activators TLR3, TLR4, the MDM2 and mTOR negative regulator of p53, the pro-apoptotic protein PUMA, and the cell death receptor Fas. Importantly a number of the genetic changes were accurately validated by protein expression changes, i.e., HSP70, p-mTOR, p-MDM2.

Conclusion: These results not only show that low dose mNPH and radiation independently increase the expression of important immune and cytotoxic genes but that the effect is greatly enhanced when they are used in combination.

Introduction

For many types of cancer, individual therapies rarely result in a cure. Therefore, the use of adjuvant-based combinatorial treatments centered around surgery, radiation and chemotherapy have become standard practice. Many of these adjuvant therapies, including hyperthermia, immunotherapy and photodynamic therapy, have been shown to work well in combination with the three primary treatment modalities [1–3]. However, in spite of thousands of positive preclinical research studies demonstrating the cancer treatment efficacy of these combination treatments, clinical trials have often failed to reach the predicted or anticipated positive clinical result. As the underlying mechanism by which clinical level hyperthermia affects living cells, alone or in combination with other modalities, remains challenging in many settings, achieving a consistent positive therapeutic effect has proven difficult. Researchers and clinicians who work in this field, believe there are two major reasons for this unfulfilled clinical promise; first that the intersection of tumor, normal tissue and hyperthermia biology is variable, inconsistent and complex in various individual treatment situations and second that current thermal dose delivery technology is not precise or selective enough, especially regarding individual cancer cell cytotoxicity or sensitization. Without such precisely targeted heating technology and detailed mechanistic tumor/normal tissue biology information, at least for invasive cancers, one strategy for advancing hyperthermia cancer treatment success is to use cell-based nanoparticle heating techniques and sublethal tumor heating to stimulate molecular anticancer immune and/or cytotoxic mechanisms such as apoptosis. This in vitro study, using melanoma cells, magnetic nanoparticle hyperthermia (mNPH), quantitative RNA genetic analysis (nanoString) and semi-quantitative protein analysis (Western blot) was designed to better understand, at the genetic and protein level, if low-dose hyperthermia alone or with modest radiation is capable of stimulating a meaningful tumor cell based immune and/or cytotoxic response. These in vitro studies do not recapitulate an in vivo setting. So, the results here do not clarify how the changes observed would influence immune reactivity in vivo. We believe our use of quantitative genetic analysis, in this setting, has resulted in...
the generation of novel cancer cell-based immunogenic and protein information, for low dose nanoparticle hyperthermia and radiation, that will allow for more specific and effective improvements in the use of these therapeutics.

Methods

Cell lines and growth conditions

B16-F10 murine melanoma cells were obtained from the American Type Culture Collection (ATCC) (Manassas, VA). The cells were plated at a density of $1.25 \times 10^5$ cells/mL and cultured in 1X Roswell Park Memorial Institute (RPMI) with 4.5 g/L glucose and L-glutamine, without sodium pyruvate (Mediatech, Inc., Manassas, VA) supplemented with 10% fetal bovine serum (FBS) (HyClone Laboratories, Inc., Logan, UT), and 1% penicillin–streptomycin solution (10,000 units/mL penicillin; 10,000 μg/mL streptomycin, HyClone Laboratories, Inc., Logan, UT). Cells were cultured on tissue culture dishes and incubated at 37°C and 5% CO₂.

Magnetic nanoparticles

All experiments were conducted with Bionized NanoFerrite (BNF) iron oxide nanoparticles (micromod Partikeltechnologie GmbH, Rostock, Germany). The dextran matrix/shell
100±30 nm (hydrodynamic diameter) mNPs were suspended in H2O. The NPs are 75–80% (w/w) magnetite and have a stock solution concentration of 45 mg/mL (24.5 mg/mL iron). The mNPs were added to the cell media for a final concentration of 3 mg/mL and incubated for 48 h pretreatment.

Figure 1. (Continued)

**AMF activation**
Following a 48 h mNPH incubation, cells were trypsinized and spun to form pellets in 1.5 mL Eppendrof tubes. Pellets contained $3 \times 10^6$ cells with 2.5 pg iron/cell ($\sim$7.5 µg iron per pellet). To generate the targeted thermal dose, the pelleted
cells were exposed to an alternating magnetic field (AMF) that was generated by a custom-built, water cooled 14 turn solenoid coil powered by a Hüttinger TIG 10/300 generator (Freiburg, Germany). The AMF was tuned to operate at 165 kHz and 300 Oe. Cell medium and near environmental temperatures were continuously monitored and kept stable using FISO fiber optic temperature monitoring probes (FISO Inc., Quebec, Canada, operated at a frequency of 1 Hz). A thermally controlled water bath surrounded the cell tubes to maintain the environmental tube temperature at 37 °C ± 1 °C. The water bath was monitored with a separate FISO temperature probe. Following AMF exposure yielding a CEM43 30, the cells were re-plated and placed into the incubator before lysing at 24 h. All mNPH treated cells received a thermal dose of CEM43 30, cumulative equivalent minutes at 43 °C for 30 min, with stable maximum temperatures between 42 and 44 °C.

Treatment conditions
To ensure the genetic and protein changes observed were associated with the mNPH, 8 Gy and mNPH + 8 Gy treatments, eight different treatment condition groups were studied (under identical experimental conditions). These control groups included: B16 cells + no treatment, cells + mNP, cells + AMF, cells + mNPH (mNPs + AMF), cells + 8 Gy, cells + 8 Gy + mNPs, cells + 8 Gy + AMF, cells + 8 Gy + mNPH (mNPs + AMF). All treatment groups, including controls, underwent pelleting and were placed in the water bath for the same amount of time as the groups that were activated by the magnetic field. This ensured that changes in expression were truly due to the treatments and not due to experimental procedure stress. As the genetic expression changes for all control groups (groups not exposed to mNPH and/or radiation) were not statistically different than no treatment we have not provided genetic response details. As such, the result section contains only genetic and protein data for mNPH, 8 Gy and mNPH + 8 Gy. These effects/data are compared to the no treatment group, also referred to as 'control'.

Radiation
Cells were irradiated using a cesium-137 irradiator at 1000 rad/minute (662 keV). Cell culture plates were given an
8 Gy dose immediately before being pelleted and placed in a temperature controlled AMF coil operated at 160 kHz and 300 Oe. 8 Gy is a regularly used clinical and research dose.

**Protein isolation and quantification**

Protein for Western blot analysis was harvested with lysate buffer (40 mM Hepes buffer, 120 mM sodium chloride, 1 mM EDTA, 2.5 mM sodium pyrophosphate, 1 mM β-glycerol-phosphate, 1% Triton-X 100, 0.01% sodium deoxycholate) 24 h post treatment, isolated and normalized with the Bradford protein assay. Traditional Western blot protocol was carried out using SDS-PAGE. Briefly, 12% polyacrylamide separating gels were used with 16 μg of lysate sample loaded per well. These gels were then transferred to nitrocellulose membranes which were then incubated in protein specific antibodies. The secondary antibodies were conjugated with horseradish peroxidase allowing for immunoreactive bands to be detected using a G:Box Syngene through enhanced chemiluminescence (New England Biogroup, Atkinson, NH). Protein expression was normalized with respect to expression of GAPDH and quantified via densitometry performed with NIH ImageJ Software. Each experiment was run three times with each replicate having its own RNA and protein analysis.

**RNA collection and analysis**

RNA was harvested and purified using the Qiagen RNeasy Mini Kit, according to the manufacturer’s instructions (Qiagen, Venlo, Netherlands). RNA concentration and purity were determined with the GeneQuant II spectrophotometer (Pharmacia Biotech, Piscataway, NJ). RNA samples were normalized so that 50 ng of RNA was used per sample for use with nanoString technologies for expression levels. The nanoString PanCancer Immune Profiling Panel (murine) combined with a custom nanoString nCounter panel (apoptosis, cell cycle, DNA damage genes), was used on our samples and quantified on the nanoString nCounter Analysis System (nanoString Technologies, Seattle, WA), according to the manufacturer’s instructions. Each sample was normalized to expression levels of the housekeeping genes, and the geometric mean was used to compute the normalization factor. Any mRNA samples below 20 counts were excluded from analysis. Results were analyzed with nSolver Analysis (v. 4.0) and Advanced Analysis Software (v. 2.0).

**Results**

In this study, our primary research findings involve the discovery of immune and cytotoxic based genetic (RNA) and protein changes following the exposure of B16 murine melanoma cells to a single mNPH dose equivalent to 30 min at 43 °C and/or a single dose of 8 Gy. We have demonstrated our genetic finding using classical KEGG pathway diagrams, a heat map and a table format. Semi-quantitative protein results are demonstrated via western immunoblots and a bar diagram. The red and green boxes denoted on the Kegg diagram (Figure 1) demonstrate important specifically altered gene and pathway expression changes.

**Magnetic nanoparticle hyperthermia gene expression**

**mNPH induced mRNA expression**

**Immune pathways.** Significant genetic changes included selected chemoattractant molecules, and immunogenic, and cytotoxic pathways. These changes are highlighted in Figure 2 in the form of a classical gene expression heatmap.

Increased expression changes (yellow) and decreased expression changes (blue) are highlighted for our various treatments across many pathways. Most notable is the marked increased expression of the thermotolerance/immunogenic HSP70 gene [4,5]. Also notable is a minimal change in expression of the chemokine CXCR3 but a significant increase in the expression of its ligands, CXCL10 and CXCL11, which are important in activating other signaling molecules that recruit immune cells for the general enhancement of anti-tumor pathways. The presence of increased CXCL10 and CXCL11 expression without a corresponding increase in CXCR3 suggests mNPH CEM43 30 generates a significant pro-immune genetic expression response (Figure 1). mNPH also generated a decrease in expression of the toll-like receptor pathway signal (TLR3, TLR4) and the associated p38/MAPK pathway. Both pathways are known to be immunosuppressive, pro-tumorigenic, and involved in apoptosis evasion [6–9]. The reduced expression of TLR3, TLR4 and p38/MAPK indicates that low level mNP heating reduces anti-apoptotic and immune suppression signals [10,11]. Changes in the toll-like receptor pathway are demonstrated in Figure 1. Genes differentially expressed in mNPH versus control are colored

| Gene     | mNPH     | 8 Gy     | mNPH 8 Gy |
|----------|----------|----------|-----------|
| ICAM-1   | .766     | 1.53     | 15.7*     |
| CD86     | 2.09     | 1.32     | 29.1*     |
| CXCL10   | 2.6*     | .657     | 2.83*     |
| CXCL11   | 1.18*    | .713     | 4.28*     |
| CXCR3    | 1.39     | 1.31     | 8.86*     |
| TLR4     | .81      | .864     | .457      |
| TLR3     | .728     | .848     | .24*      |
| ERK1 (MAPK3) | .478*  | 1.06     | .402*     |
| ERK2 (MAPK1) | .837   | .882     | .564*     |
| MAPK11   | .619     | .838     | .2*       |
| MAPK14   | 1.15     | .85      | .842      |
| Bcl-2    | 1.53     | 1.19     | .982      |
| Bax      | 1.38     | 1.46*    | 1.14      |
| PUMA (bcb3) | 1.04   | 1.53     | 4.75*     |
| CASP8    | .687*    | .893     | .572*     |
| CASP3    | .638     | .976     | .343*     |
| Gadd45   | 3.38*    | 1.21     | 4.65*     |
| Bim (bcl211) | .481   | 1.09     | .364*     |
| survivin | .373     | .923     | .1*       |
| mTOR     | .902     | .898     | .781      |
| HSP70 (hsapb1) | 57*    | .884     | 41.8*     |
| MDM2     | 3.61*    | 1.65*    | 3.12*     |
| Fas      | 2.08*    | 1.54     | 6.85*     |

These expression changes were amplified with the addition of radiation. Other notable genes such as the pro-apoptotic gene bcb3 (PUMA) were altered mostly by the combination treatment.

*Statistically significant at p < .05, differential expression.
on the KEGG pathway map demonstrating increases (yellow) and decreases (blue) in genes and their consequences. mNPH CEM43 30 also induced a significant increase in CD86, this gene has been closely associated with immunogenic cell death (ICD).

**Cell death pathways.** In this study, important members of the Ras/Raf/MAPK pro-survival signaling pathway, ERK1 and ERK2, were downregulated following mNPH, compared to control. Although ERK has both a pro-survival and pro-apoptotic function, depending on the environment, ERK is more likely pro-apoptotic in this setting [9,12,13]. Similarly, the cell death receptor Fas was upregulated following mNPH CEM43 30, indicating a pro-apoptotic response [14]. The DNA repair protein, Gadd45, which plays a role in determining cell survival/apoptosis, was overexpressed following mNPH CEM43 30, also suggesting a pro-apoptotic response [15,16]. Other common pro-apoptotic pathways include the increased expression of several caspase family genes. Our mNPH CEM43 30 RNA results demonstrate lowered expression of CASP8 and CASP3, compared to control, possibly indicating the modest stimulus was too low to initiate the caspase

---

**Figure 3.** These volcano plots demonstrate differential gene expression fold change following 8 Gy, mNPH or mNPH + 8 Gy, compared to control (on an x-axis log2 scale, with the associated p values). Volcano plots demonstrate gene expression folds changes in two ways: data points moving to the left or right, from the zero point demonstrate positive or negative expression fold change (circles). The higher the data points rest on the y-axis the more statistically significant the change. In this volcano plot, the yellow circles represent those in the cytokine/cytokine receptor pathway. These results suggest that neither 8 Gy nor mNPH alone is a dominant expression promoting factor; rather, the treatments appear to work synergistically together to alter gene expression. The gray circles represent altered genes that not immune or cytotoxicity based. The open circles represent genes who altered expression is not statistically significant at p ≤ .05.
triggered apoptotic activity or that a different apoptotic pathway is activated [14]. A lack of change in PUMA, Bax, Fadd, Bid and GzmA/GzmB, combined with a decrease in Bim, all common pro-apoptotic gene expression patterns, leads to additional questions regarding the robustness of mNPH CEM43 30 to stimulate apoptosis, in vitro, at multiple levels.

Magnetic nanoparticle hyperthermia + radiation gene expression

mNPH + radiation immune related mRNA expression

Immune pathways. As noted, we compared genetic changes for mNPH (CEM43 30), 8 Gy radiation and in combination. Table 1 demonstrates differential expression changes, select group of genes, for all three treatments compared to control. While this study is focused on mNPH and mNPH + radiation, it is important to note that radiation alone did not demonstrate a greater immune or cytotoxic gene enhancement, in any gene or pathway, compared with mNPH + radiation. Compared to mNPH alone, mNPH + radiation significantly increased the expression of notable immune and apoptotic genes such as TLR4, TLR3, CXCL11 and CD86. Expression of the potent immunogenic gene, ICAM1, which codes for a ligand that binds to and activates leukocytes, was not increased following mNPH but was significantly increased following the combined treatment [17,18].

Cell death pathways. Virtually all of the cell death pathways activated by mNPH were activated to a greater extent by the combined mNPH + radiation treatment. Genes such as ERK2, CASP3, MAPK11 (p38b), Fas and PUMA demonstrated significantly enhanced expression. As with mNPH alone, decreases in ERK2 and MAPK11 expression, following mNPH + radiation could demonstrate a reduction in tumor cell survival signaling through the p38/MAPK pathway. Greater increases in PUMA expression, a well-known pro-apoptotic gene, along with an increase in cell death receptor Fas, demonstrate enhanced activation of the apoptotic cascades following mNPH + radiation to activate to a greater degree than mNPH or radiation.

As mentioned previously, the combination mNPH + 8 Gy treatment resulted in a near uniform increase immune and cell death gene expression compared to either single treatment. The first two volcano plots in Figure 3 demonstrate the elevation and significance of gene expression following mNPH and 8 Gy alone. The third plot demonstrates the marked gene expression changes following the combination treatment. Plot 3 demonstrates just how effective a low dose hyperthermia and radiation treatment can be in generating a genetic immune and cell death pathway response.

Magnetic nanoparticle hyperthermia ± radiation induced protein expression

To verify that the changes in RNA were translated, we examined protein expression in 12 select targets. Of the 12 targets examined, only three showed differential protein expression; HSP70, p-MDM2 and p-mTOR were markedly over expressed via Western blot and in concern with gene expression. Figure 4 shows a representative Western blot, with densitometry across all blots represented by mean fold expression changes in the corresponding bar graph. HSP70, an important cellular regulator of various types of cell stress, including hyperthermia and immune signaling, demonstrated a 57 × RNA and 3 × protein increasing expression, respectively, following CEM43 30, as compared to control. The HSP70 increase following mNPH + radiation was not quite as great as mNPH alone suggesting radiation may slightly mute the response. Both mNPH treatments resulted in an increase in MDM2 gene expression and a decrease in the p-MDM2 protein. p-MDM2 is the activated form of the protein and requires phosphorylation via other proteins, thus an increase in mRNA or total MDM2 protein will not necessarily translate to an increase in the activated (p-MDM2) form. This finding cannot be fully explained from these data; however, the MDM2 gene is associated with p53 negative feedback loop that promotes cell growth and proliferation [19,20], a decrease in p-MDM2 protein expression suggests a tumor suppressing effect mediated through p53. It is important to note that p53 is not mutated in B16F10 murine melanoma cells [21]. mNPH alone and mNPH + radiation had no effect on the genetic expression of mTOR, which has generally been considered an indicator of cell growth and proliferation; however, there was a significant decrease in p-mTOR protein expression following all treatment modalities [12,22].

Figure 4. These western/immune blots demonstrate the effect of mNPH CEM 30, 8 Gy and 8 Gy + mNPH had on various protein expression level, with GAPDH as a loading sample. Although mNPH and 8 Gy/mNPH had lower GAPDH than the other conditions, the amount of HSP70 protein was dramatically greater, as was p-mTOR. Additionally, p-MDM2 expression was very significantly decreased following hyperthermia and combinatorial treatments.
The above discussed results include both positive (pro-immune/pro-apoptotic) and negative (anti-immune/anti-apoptotic) gene expression effects, which are summarized in Figure 5. The balance of these effects is what will determine how effective a therapy is in the long term.

**Discussion**

These studies provide quantifiable evidence that a low thermal dose (CEM43 30/thermal dose equivalent to 30 min at 43°C) generated by mNPH increases the expression of...
anti-cancer immune and cell death pathway genes and proteins in cultured melanoma cells. A number of the most significant activations, such as cytokine–cytokine receptor pathways including cancer regulating chemokines CXCL10, CXCL11, the T-cell trafficking chemokine CXCR3 [23,24] and the toll-like receptor signaling pathways TLR3/TIR4 are drivers of well accepted anti-tumor or pro-immune response groups. A number of the positively expressed genes and pathways have been demonstrated to directly affect specific anti-cancer immune cell subtypes and, depending on the cell type, could result in different pathophysiological activities. It is also, of course, true that our findings could have different implications in multicell tissues settings. With regard to the apoptosis pathways, our results demonstrate both pro-apoptotic and anti-apoptotic changes are stimulated by mNPH. The balance between these changes, and the function of the genes with altered expression are important in understanding the true effect and balance of the apoptotic pathways.

Our studies also showed that a number of genes involved in injury, repair, survival and immune signaling including Gadd45, Bim, survivin, MDM2, ERK1 and CASP8, are stimulated (altered expression) more by mNPH alone than by 8 Gy or even mNPH + 8 Gy. The changes seen in genes such as ERK1, and survivin, demonstrate how low dose mNPH can effectively activate immune and cell death related pathways, in cancer cells. It is important to note that the expression level of the important immune and cytotoxic ERK1 gene/p-ERK protein was affected differently, by mNPH, depending on the amount of mNPs used in the experiment. If enough mNPs were used to create a measurable thermal dose we found ERK1 expression to be decreased; however, when the identical experiment was conducted, but with fewer mNPs and no measurable thermal dose, an increase in p-ERK protein expression was found.

Although we have not performed genetic validation such as pathway blocks or gene knockout studies, our evidence suggests a number of important potential cancer therapy leads including the TLR3 and TLR4, expressed by tumor cells, may activate cytokine pathways that lead to immune cell recruitment and an inflammatory response via the MyD88 pathway. Interestingly the decreased TLR4 and TLR3 RNA signal seen in our study did not prevent a high expression of MyD88 [6,25]; the down regulation of the p38/MAPK pathway, upregulation of the cell cycle associated gene p21 and the increased Gadd45 expression suggest cell cycle arrest and pro-apoptosis.

Recent studies demonstrating a decrease in p38 and a potential increase in pro-apoptotic PUMA pathway, support our results demonstrating involvement of p38/MAPK pathway following mNPH treatments [10]. Finally, while some of our mNPH and radiation data show a decrease in CASP3 and the possibility of apoptotic pathway suppression, other apoptotic pathways appear, simultaneously, activated.

Finally, it is important to mention again that while these studies contain potentially valuable hyperthermia and radiation immunomodulation and cell death pathway information, without validation in additional cells lines, the data remain in the promising discovery category.

Acknowledgements

The authors thank Christian Lytle, the Administrative Coordinator for Shared Resources at the Norris Cotton Cancer Center for his help with nanoString and RNA analysis. The following Norris Cotton Cancer Center shared resources: Pre-clinical Imaging, Irradiation and Microscopy Shared Resource (irradiation) and the Genomics and Molecular Biology Shared Resource (nanoString Prep Station and nCounter System).

Disclosure statement

The authors have no conflicts of interest to disclose.

Funding

The study is supported by the National Cancer Institute through NCI U01 CA218292, NCI P30 CA023108 and Philanthropic support from Friends of the Norris Cotton Cancer Center.

ORCID

Kayla E. A. Duval [http://orcid.org/0000-0001-5854-3735]

References

[1] Chen W, Zhang J. Using nanoparticles to enable simultaneous radiation and photodynamic therapies for cancer treatment. J Nanosci Nanotechnol. 2016;6:1159–1166.
[2] Horsman MR, Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol. 2007;19:418–426.
[3] Kalbasi A, June CH, Haas N, et al. Radiation and immunotherapy: a synergistic combination. J Clin Invest. 2013;123:2756–2763.
[4] Frey B, Weiss EM, Rubner Y, et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperth. 2012;28:528–542.
[5] Multhoff G. Heat shock proteins in immunity. Handb Exp Pharmacol. 2006;(172):279–304.
[6] Goto Y, Arigami T, Kitago M, et al. Activation of toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 2008;7:3642–3653.
[7] He W, Liu Q, Wang L, et al. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007;44:2850–2859.
[8] Huang B, Zhao J, Li H, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 2005;65:5009–5014.
[9] Lopez-Bergami P. The role of mitogen- and stress-activated protein kinase pathways in melanoma. Pigment Cell Melanoma Res. 2011;24:902–921.
[10] Keuling AM, Andrew SE, Tron VA. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA. Pigment Cell Melanoma Res. 2010;23:430–440.
[11] Estrada Y, Dong J, Ossowski L. Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation. Pigment Cell Melanoma Res. 2009;22:66–76.
[12] Lasithiotakis KG, Sinnberg TW, Schittek B, et al. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J Invest Dermatol. 2008;128:2013–2023.
Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene. 2004;23:2838–2849.

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495–516.

Tamura RE, de Vasconcellos JF, Sarkar D, et al. GADD45 proteins: central players in tumorigenesis. Curr Mol Med. 2012;12:634–651.

Cretu A, Sha X, Tront J, et al. Stress sensor Gadd45 genes as therapeutic targets in cancer. Cancer Ther. 2009;7:268–276.

Altomonte M, Gloghini A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 1993;53:3343–3348.

Webb DS, Mostowski HS, Gerrard TL. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol. 1991;146:3682–3686.

Karni-Schmidt O, Lokshin M, Prives C. The roles of MDM2 and MDMX in cancer. Annu Rev Pathol Mech Dis. 2016;11:617–644.

Onel K, Cordon-Cardo C. MDM2 and prognosis. Mol Cancer Res. 2004;2:1–8.

Melnikova VO, Bolshakov SV, Walker C, et al. Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene. 2004;23:2347–2356.

Karbownikczek M, Spittle CS, Morrison T, et al. mTOR is activated in the majority of malignant melanomas. J Invest Dermatol. 2008;128:980–987.

Kuo PT, Zeng Z, Salim N, et al. The role of CXCR3 and its chemokine ligands in skin disease and cancer. Front Med. 2018;5:271.

Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/ CXCR3 axis for immune activation-a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–47.

Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008;57:1271–1278.